Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration

S. Su, Y. Li, Y. Luo, Y. Sheng, Y. Su, R. N. Padia, Z. K. Pan, Zheng Dong, Shuang Huang

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Proteinase-activated receptor 2 (PAR2) is a G protein-coupled receptor that is activated by trypsin-like proteinases. PAR2 is detected in breast tumor specimens; however, it is not clear how PAR2 level in breast cancer cell/tissues compares with normal cell/tissues. Here, we show the elevation of PAR2 protein level in 76 of 105 breast tumor specimens but only 5 of 24 normal breast tissues. PAR2 level is also higher in breast cancer cell lines than that in normal breast cells and non-cancerous breast cell lines. To determine the role of PAR2 in breast carcinogenesis, we examined the effect of PAR2 agonists on cell proliferation and migration. Our studies show that PAR2 agonists (PAR2-activating peptide and trypsin) are neither potent growth enhancers nor chemoattractants to breast cancer cells. Instead, PAR2 agonists induce significant chemokinesis. PAR2-mediated chemokinesis is Gαi- dependent, and inhibiting Src kinase activity or silencing c-Src expression blocks PAR2-mediated chemokinesis. These results suggest that c-Src works downstream of Gαi to mediate this PAR2 agonist-induced event. To characterize c-Src effector, we reveal that PAR2 agonists activate JNKs in a Src-dependent manner and that JNK activity is essential for PAR2-mediated chemokinesis. Moreover, PAR2 agonist stimulation leads to paxillin Ser 178 phosphorylation and paxillin(S178A) mutant inhibits PAR2-mediated chemokinesis. In conclusion, our studies show that PAR2 agonists facilitate breast cancer cell chemokinesis through the Gαi-c-Src-JNK- paxillin signaling pathway.

Original languageEnglish (US)
Pages (from-to)3047-3057
Number of pages11
JournalOncogene
Volume28
Issue number34
DOIs
StatePublished - Aug 27 2009

Fingerprint

PAR-2 Receptor
Cell Movement
Breast Neoplasms
Paxillin
Breast
Trypsin

Keywords

  • Breast cancer
  • Chemokinesis
  • JNK
  • PAR2
  • Paxillin
  • Src

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Su, S., Li, Y., Luo, Y., Sheng, Y., Su, Y., Padia, R. N., ... Huang, S. (2009). Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration. Oncogene, 28(34), 3047-3057. https://doi.org/10.1038/onc.2009.163

Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration. / Su, S.; Li, Y.; Luo, Y.; Sheng, Y.; Su, Y.; Padia, R. N.; Pan, Z. K.; Dong, Zheng; Huang, Shuang.

In: Oncogene, Vol. 28, No. 34, 27.08.2009, p. 3047-3057.

Research output: Contribution to journalArticle

Su, S, Li, Y, Luo, Y, Sheng, Y, Su, Y, Padia, RN, Pan, ZK, Dong, Z & Huang, S 2009, 'Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration', Oncogene, vol. 28, no. 34, pp. 3047-3057. https://doi.org/10.1038/onc.2009.163
Su, S. ; Li, Y. ; Luo, Y. ; Sheng, Y. ; Su, Y. ; Padia, R. N. ; Pan, Z. K. ; Dong, Zheng ; Huang, Shuang. / Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration. In: Oncogene. 2009 ; Vol. 28, No. 34. pp. 3047-3057.
@article{325e6ff9dfe54892a0c010a7081acace,
title = "Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration",
abstract = "Proteinase-activated receptor 2 (PAR2) is a G protein-coupled receptor that is activated by trypsin-like proteinases. PAR2 is detected in breast tumor specimens; however, it is not clear how PAR2 level in breast cancer cell/tissues compares with normal cell/tissues. Here, we show the elevation of PAR2 protein level in 76 of 105 breast tumor specimens but only 5 of 24 normal breast tissues. PAR2 level is also higher in breast cancer cell lines than that in normal breast cells and non-cancerous breast cell lines. To determine the role of PAR2 in breast carcinogenesis, we examined the effect of PAR2 agonists on cell proliferation and migration. Our studies show that PAR2 agonists (PAR2-activating peptide and trypsin) are neither potent growth enhancers nor chemoattractants to breast cancer cells. Instead, PAR2 agonists induce significant chemokinesis. PAR2-mediated chemokinesis is Gαi- dependent, and inhibiting Src kinase activity or silencing c-Src expression blocks PAR2-mediated chemokinesis. These results suggest that c-Src works downstream of Gαi to mediate this PAR2 agonist-induced event. To characterize c-Src effector, we reveal that PAR2 agonists activate JNKs in a Src-dependent manner and that JNK activity is essential for PAR2-mediated chemokinesis. Moreover, PAR2 agonist stimulation leads to paxillin Ser 178 phosphorylation and paxillin(S178A) mutant inhibits PAR2-mediated chemokinesis. In conclusion, our studies show that PAR2 agonists facilitate breast cancer cell chemokinesis through the Gαi-c-Src-JNK- paxillin signaling pathway.",
keywords = "Breast cancer, Chemokinesis, JNK, PAR2, Paxillin, Src",
author = "S. Su and Y. Li and Y. Luo and Y. Sheng and Y. Su and Padia, {R. N.} and Pan, {Z. K.} and Zheng Dong and Shuang Huang",
year = "2009",
month = "8",
day = "27",
doi = "10.1038/onc.2009.163",
language = "English (US)",
volume = "28",
pages = "3047--3057",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "34",

}

TY - JOUR

T1 - Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration

AU - Su, S.

AU - Li, Y.

AU - Luo, Y.

AU - Sheng, Y.

AU - Su, Y.

AU - Padia, R. N.

AU - Pan, Z. K.

AU - Dong, Zheng

AU - Huang, Shuang

PY - 2009/8/27

Y1 - 2009/8/27

N2 - Proteinase-activated receptor 2 (PAR2) is a G protein-coupled receptor that is activated by trypsin-like proteinases. PAR2 is detected in breast tumor specimens; however, it is not clear how PAR2 level in breast cancer cell/tissues compares with normal cell/tissues. Here, we show the elevation of PAR2 protein level in 76 of 105 breast tumor specimens but only 5 of 24 normal breast tissues. PAR2 level is also higher in breast cancer cell lines than that in normal breast cells and non-cancerous breast cell lines. To determine the role of PAR2 in breast carcinogenesis, we examined the effect of PAR2 agonists on cell proliferation and migration. Our studies show that PAR2 agonists (PAR2-activating peptide and trypsin) are neither potent growth enhancers nor chemoattractants to breast cancer cells. Instead, PAR2 agonists induce significant chemokinesis. PAR2-mediated chemokinesis is Gαi- dependent, and inhibiting Src kinase activity or silencing c-Src expression blocks PAR2-mediated chemokinesis. These results suggest that c-Src works downstream of Gαi to mediate this PAR2 agonist-induced event. To characterize c-Src effector, we reveal that PAR2 agonists activate JNKs in a Src-dependent manner and that JNK activity is essential for PAR2-mediated chemokinesis. Moreover, PAR2 agonist stimulation leads to paxillin Ser 178 phosphorylation and paxillin(S178A) mutant inhibits PAR2-mediated chemokinesis. In conclusion, our studies show that PAR2 agonists facilitate breast cancer cell chemokinesis through the Gαi-c-Src-JNK- paxillin signaling pathway.

AB - Proteinase-activated receptor 2 (PAR2) is a G protein-coupled receptor that is activated by trypsin-like proteinases. PAR2 is detected in breast tumor specimens; however, it is not clear how PAR2 level in breast cancer cell/tissues compares with normal cell/tissues. Here, we show the elevation of PAR2 protein level in 76 of 105 breast tumor specimens but only 5 of 24 normal breast tissues. PAR2 level is also higher in breast cancer cell lines than that in normal breast cells and non-cancerous breast cell lines. To determine the role of PAR2 in breast carcinogenesis, we examined the effect of PAR2 agonists on cell proliferation and migration. Our studies show that PAR2 agonists (PAR2-activating peptide and trypsin) are neither potent growth enhancers nor chemoattractants to breast cancer cells. Instead, PAR2 agonists induce significant chemokinesis. PAR2-mediated chemokinesis is Gαi- dependent, and inhibiting Src kinase activity or silencing c-Src expression blocks PAR2-mediated chemokinesis. These results suggest that c-Src works downstream of Gαi to mediate this PAR2 agonist-induced event. To characterize c-Src effector, we reveal that PAR2 agonists activate JNKs in a Src-dependent manner and that JNK activity is essential for PAR2-mediated chemokinesis. Moreover, PAR2 agonist stimulation leads to paxillin Ser 178 phosphorylation and paxillin(S178A) mutant inhibits PAR2-mediated chemokinesis. In conclusion, our studies show that PAR2 agonists facilitate breast cancer cell chemokinesis through the Gαi-c-Src-JNK- paxillin signaling pathway.

KW - Breast cancer

KW - Chemokinesis

KW - JNK

KW - PAR2

KW - Paxillin

KW - Src

UR - http://www.scopus.com/inward/record.url?scp=69449094721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69449094721&partnerID=8YFLogxK

U2 - 10.1038/onc.2009.163

DO - 10.1038/onc.2009.163

M3 - Article

C2 - 19543320

AN - SCOPUS:69449094721

VL - 28

SP - 3047

EP - 3057

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 34

ER -